Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 1, 2016, Pages 355-358

  Wang, Hongmin ^a   Zhang, Xiaohong ^b   Liu, Xinkui ^a   Liu, Kangdong ^b   Li, Yuexia ^a   Xu, Haijiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Bronchoalveolar lavage fluid; lung cancer; serum tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; ANTIGEN CYFRA21.1; CYTOKERATIN 19; ENOLASE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; BRONCHOALVEOLAR LAVAGE FLUID; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC BRONCHITIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG ABSCESS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG FIBROSIS; LUNG LESION; LUNG TUBERCULOSIS; MALE; PNEUMONIA; PROTEIN BLOOD LEVEL; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; TUMOR DIFFERENTIATION; ADENOCARCINOMA; BLOOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS;

EID: 84966668190     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.162111     Document Type: Article

References (24)

1. Dyzmann-Sroka A, Malicki J. Cancer incidence and mortality in the greater poland region-analysis of the year 2010 and future trends. Rep Pract Oncol Radiother 2014;19:296-300.
2. Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004;98:357-62.
3. Qin HF, Qu LL, Liu H, Wang SS, Gao HJ. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2013;14:4205-8.
4. Kostovski M, Petrushevska G. Antigenic phenotype of lung carcinomas: Usual spectrum of distribution of thyroid transcription factor-1, cytokeratin 7, cytokeratin 20, and neuron specific enolase-basic immunohistochemical study of 21 cases. Prilozi 2014;35:199-207.
5. Gao J, Lv F, Li J, Wu Z, Qi J. Serum cytokeratin 19 fragment, CK19-2G2, as a newly identified biomarker for lung cancer. PLoS One 2014;9:e101979.
6. Heng SC, Chen SC, Morrissey CO, Thursky K, Manser RL, De Silva HD, et al. Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagn Microbiol Infect Dis 2014;79:322-7.
7. Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res 2014;34:3205-10.
8. Bastawisy AE, Azzouny ME, Mohammed G, Allah AA, Behiry E. Serum cytokeratin 19 fragment in advanced lung cancer: Could we eventually have a serum tumor marker? Ecancermedicalscience 2014;8:394.
9. Wu HH, Wang PH, Yeh JY, Chen YJ, Yen MS, Huang RL, et al. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cance. Taiwan J Obstet Gynecol 2014;53:30-4.
10. Burotto M, Thomas A, Subramaniam D, Giaccone G, Rajan A. Biomarkers in early-stage non-small-cell lung cancer: Current concepts and future directions. J Thorac Oncol 2014;9:1609-17.
11. Zhou F, Chen J, Tao G, Zhu M, Xie W, Cao X. Increased levels of exhaled sICAM1, sVCAM1, and sE-selectin in patients with non-small cell lung cancer. Respir Med 2014;108:1670-6.
12. Uribarri M, Hormaeche I, Zalacain R, Lopez-Vivanco G, Martinez A, Nagore D, et al. A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis. J Thorac Oncol 2014;9:1504-12.
13. Chen L, Li Q, Zhou XD, Shi Y, Yang L, Xu SL, et al. Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients. Int Immunopharmacol 2014;20:74-80.
14. Chen Z, Xu Z, Sun S, Yu Y, Lv D, Cao C, et al. TGF-β1, IL-6, and TNF-α in bronchoalveolar lavage fluid: Useful markers for lung cancer? Sci Rep 2014;4:5595.
15. Yin QQ, Jiao WW, Han R, Jiao AX, Sun L, Tian JL, et al. Rapid diagnosis of childhood pulmonary tuberculosis by Xpert MTB/RIF assay using bronchoalveolar lavage fluid. Biomed Res Int 2014;2014:310194.
16. Yin X, Xie L, Chai Y, Fan H, Han X, Feng Z. Surfactant protein b expression in bronchoalveolar lavage fluid of full-term neonates with respiratory distress syndrome. Acta Clin Croat 2014;53:161-5.
17. Houston KA, Henley SJ, Li J, White MC, Richards TB. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer 2014;86:22-8.
18. Kong J, Xu F, He M, Chen K, Qian B. The incidence of lung cancer by histological type: A population-based study in Tianjin, China during 1981-2005. Respirology 2014;19:1222-8.
19. Bia D, Zócalo Y, Armentano R, Camus J, Forteza Ed, Cabrera-Fischer E. Increased reversal and oscillatory shear stress cause smooth muscle contraction-dependent changes in sheep aortic dynamics: Role in aortic balloon pump circulatory support. Acta Physiol (Oxf) 2008;192:487-503.
20. Yang H, Mi R, Wang Q, Wei X, Yin Q, Chen L, et al. Expression of neuron-specific enolase in multiple myeloma and implications for clinical diagnosis and treatment. PLoS One 2014;9:e94304.
21. Sreenarasimhaiah J, Lara LF, Jazrawi SF, Barnett CC, Tang SJ. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts. JOP 2009;10:163-8.
22. Buil-Bruna N, López-Picazo JM, Moreno-Jiménez M, Martín-Algarra S, Ribba B, Trocóniz IF. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients. AAPS J 2014;16:609-19.
23. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches. J Thorac Oncol 2012;7:306-15.
24. Woodhams R, Nishimaki H, Fujii K, Kakita S, Hayakawa K. Usefulness of multidetector-row CT (MDCT) for the diagnosis of non-occlusive mesenteric ischemia (NOMI): Assessment of morphology and diameter of the superior mesenteric artery (SMA) on multi-planar reconstructed (MPR) images. Eur J Radiol 2010;76:96-102.